GlassScriptPhysician profile
Russell Wardlaw
NPI 1376734210
$8,240.26
in general payments reported to CMS, 2019-2025
28 companies · $941 in 2025
The $941 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,622 · 2020: $779 · 2021: $1,396 · 2022: $1,414 · 2023: $1,037 · 2024: $1,051 · 2025: $941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,028.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,932.86 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Allergan, INC. | $862.15 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $635.33 | 2019-2025 | Entyvio |
| Genzyme Corporation | $552.40 | 2022-2025 | |
| Janssen Biotech, INC. | $494.42 | 2019-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $486.82 | 2019-2024 | Xifaxan |
| Celgene Corporation | $389.44 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $374.73 | 2019-2022 | |
| Pfizer INC. | $249.98 | 2019-2021 | |
| Boston Scientific Corporation | $243.31 | 2021-2024 | Orcapod, Captivator II |
| Merck Sharp & Dohme LLC | $162.43 | 2019-2022 | |
| Enterra Medical, INC. | $153.15 | 2022 | |
| Phathom Pharmaceuticals, INC. | $119.69 | 2024 | Voquezna |
| Janssen Scientific Affairs, LLC | $91.31 | 2020 | |
| Ardelyx, INC. | $91.18 | 2022-2024 | Ibsrela |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $88.06 | 2024-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $75.64 | 2019-2025 | |
| Qol Medical, LLC | $48.45 | 2019-2022 | |
| Ucb, INC. | $39.99 | 2019 | |
| Amgen INC. | $22.13 | 2023 | Avsola |
| Conmed Corporation | $21.78 | 2023 | Conmed Biliary |
| Aimmune Therapeutics, INC. | $17.66 | 2025 | Vowst |
| Mauna Kea Technologies, INC. | $16.02 | 2024 | |
| Intra-Sana Laboratories | $15.80 | 2024 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Lilly USA, LLC | $15.19 | 2024 | Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.00 | 2023 | Cyltezo |
| Nestle Healthcare Nutrition INC. | $13.56 | 2022 | |
| Redhill Biopharma INC. | $11.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Wardlaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.